Last €58.62 EUR
Change Today +0.225 / 0.39%
Volume 0.0
JUD On Other Exchanges
New York
As of 1:58 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (JUD) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - €59.05
52 Week Low
02/4/14 - €43.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ST JUDE MEDICAL INC (JUD)

st jude medical inc (JUD) Related Businessweek News

View More BusinessWeek News

st jude medical inc (JUD) Details

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems that provide therapy to patients suffering from heart conditions, such as sudden cardiac arrest; and cardiac resynchronization therapy devices to treat patients suffering from heart failure. It also provides pacemakers for patients whose hearts beat too slowly or who suffer from other cardiac arrhythmias; leads to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment, which are used by physicians and healthcare professionals to program cardiac rhythm management devices and analyze device data to enhance patient management. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, vascular plugs, percutaneous catheter introducers, and diagnostic guidewires; and transcatheter aortic heart valves, heart valve repair and replacement products, and transcatheter structural heart defect devices. Further, it provides electrophysiology introducers and catheters, and ablation systems, as well as cardiac mapping, navigation, and recording systems for diagnosing and treating various irregular heart rhythms. Additionally, the company offers neurostimulation systems for chronic pain, such as rechargeable and primary cell implantable pulse generators. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in Saint Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/14
Founded in 1976

st jude medical inc (JUD) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $430.0K
Chief Operating Officer
Total Annual Compensation: $730.0K
President of International Division
Total Annual Compensation: $752.4K
Executive Vice President
Total Annual Compensation: $730.0K
Compensation as of Fiscal Year 2013.

st jude medical inc (JUD) Key Developments

St. Jude Medical Inc. Reaffirms Earnings Guidance for the Fourth Quarter Ended January 3, 2015

St. Jude Medical inc. reaffirmed earnings guidance for the fourth quarter ended January 3, 2015. For the quarter ended January 3, 2015, the company expects to report net sales of approximately $1.44 billion, up slightly from $1.42 a year earlier. The company's prior guidance range had been $1.39 billion to $1.47 billion. On a currency-neutral basis, its fourth quarter net sales increased by approximately 5% from the prior-year period. The company reaffirmed its forecast for fourth quarter adjusted EPS in a range of $1.02 to $1.04.

St. Jude Medical, Inc. Announces First Patient Enrollment in STAR-VT Clinical Trial

St. Jude Medical Inc. announced the first patient enrollment in the STAR-VT (Substrate Targeted Ablation using the FlexAbility Ablation Catheter System for the Reduction of Ventricular Tachycardia) clinical trial, a prospective, multi-center, randomized study evaluating the safety and efficacy of the FlexAbility ablation catheter when used in ventricular tachycardia (VT) ablation procedures. The STAR-VT trial will assess whether combining targeted ablation with either an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) can reduce the incidence and economic burden of recurring ventricular arrhythmias better than treatment with either an ICD or CRT-D and medication alone.

St. Jude Medical Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:30 AM

St. Jude Medical Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Daniel J. Starks, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €58.62 EUR +0.225

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $14.74 USD -0.22
CR Bard Inc $177.27 USD -1.18
Smith & Nephew PLC 1,175 GBp -11.00
Terumo Corp ¥2,878 JPY -4.00
Zimmer Holdings Inc $116.23 USD -0.84
View Industry Companies

Industry Analysis


Industry Average

Valuation JUD Industry Range
Price/Earnings 21.8x
Price/Sales 3.4x
Price/Book 4.6x
Price/Cash Flow 21.5x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at